Difference between revisions of "Adrenocortical carcinoma - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "8 PubMed" to "8/ PubMed") |
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8})" to "[https://clinicaltrials.gov/ct2/show/$1 Clinical Trial Registry]") |
||
| Line 24: | Line 24: | ||
===References=== | ===References=== | ||
| − | # '''GALACCTIC:''' Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. [https://doi.org/10.1016/S1470-2045(15)70081-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25795408/ PubMed] NCT00924989 | + | # '''GALACCTIC:''' Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. [https://doi.org/10.1016/S1470-2045(15)70081-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25795408/ PubMed] [https://clinicaltrials.gov/ct2/show/NCT00924989 Clinical Trial Registry] |
[[Category:Adrenocortical carcinoma regimens]] | [[Category:Adrenocortical carcinoma regimens]] | ||
Revision as of 15:30, 31 May 2023
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main adrenocortical carcinoma page for current regimens.
Recurrent, locally advanced, or metastatic disease
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Fassnacht et al. 2015 (GALACCTIC) | 2009-2011 | Phase 3 (C) | Linsitinib | Did not meet primary endpoint of OS Median OS: 356 vs 323 days |
No active antineoplastic treatment.
References
- GALACCTIC: Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. link to original article PubMed Clinical Trial Registry